CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
Recruiting · NCT07615348 · Registry updated 2026-08-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk | Clear-cell metastatic renal cell carcinoma | Recruiting | Phase 2 | 2026-08-11 | NCT07615348 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jinling Hospital, China | 33 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University | Nanjing | China | 5 |
| Nanjing First Hospital, Nanjing Medical University | Nanjing | China | 12 |
| Sir Run Run Hospital, Nanjing Medical University | Nanjing | China | 1 |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing | China | 43 |
| Wuxi No.2 People's Hospital (Jiangnan University Medical Center) | Wuxi | China | 1 |